Totaligent signs binding LOI for JV with GloMed and call option to acquire GloMed for $3M cash + 15% equity

Totaligent, Inc.

GloMed has ~$10M annual revenue and ~$1M free cash flow; distributes biologics/devices in APAC via 20+ KOLs.
JV will combine Aetherium Medical platform with GloMed's infrastructure; no upfront cash; incremental revenue shared.
Call option to buy 100% of GloMed within 1 year for $3M cash plus 15% of Totaligent's fully diluted common stock.
Target JV closing March 22, 2026; subject to due diligence, definitive agreements, and PCAOB audit for option exercise.
Exclusivity through April 22, 2026; board seats: DeFeudis, Heath, Klarich; Totaligent appoints 3 seats for strategic control.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Totaligent, Inc. entered into Binding Letter of Intent with GloMed Solutions Limited Liability Company (effective 2026-02-22).

Action: entry
Counterparty: GloMed Solutions Limited Liability Company
Effective: 2026-02-22

Exact text from the filing

On February 22, 2026, Totaligent, Inc. (the “Company”) entered into a Binding Letter of Intent (the “LOI”) with GloMed Solutions Limited Liability Company (“GloMed”).

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

Totaligent, Inc. filing history →

Source: SEC EDGAR

accession 0001477932-26-001016

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.